Consensus for 2023 total revenue is $196.43M.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AKBA:
- Akebia Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Business Highlights
- Akebia receives positive CHMP opinion in Europe for Vafseo
- Akebia receives second interim response from FDA for vadadustat FDR
- Akebia should update on vadadustat FDA process in next month, says Piper Sandler